The Efficacy and Safety of SGF200 on Immune Enhancement
- Conditions
- Immunity
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: SGF200 group
- Registration Number
- NCT04930640
- Lead Sponsor
- Chonbuk National University Hospital
- Brief Summary
This study was conducted to investigate the efficacy and safety of SGF200 on immune enhancement.
- Detailed Description
This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 100 subjects were randomly divided into SGF200 group or placebo group. The investigators measured Natural Killer cell activity, Cytokines(IL-2, IL-12, IFN-γ, TNF-α), questionnaire scores of upper airway infection.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Adult men and women over 50 years
- After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice
-
If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕
-
Those who received influenza vaccination within 3 months before first intake for test product
-
Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg / m^2 at the screening
-
Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic
-
Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening
-
Those who have received antipsychotic medication within 3 months before screening
-
Those who alcoholic or drug abuse suspected
-
Those who participated in other clinical trials within 3 months before screening
-
Laboratory test by show the following results
- Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit
- Serum Creatinine > 2.0 mg/dL
-
Pregnancy or breast feeding
-
Those who doesn't accept the implementation of appropriate contraception of a childbearing woman
-
Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo group Placebo 1 times a day, 1 capsule for 1 time, before breakfast meal\[350 mg/day (Bacillus amyloliquefaciens spore 0 CFU/day, GF101 0 U/day)\] SGF200 group SGF200 group 1 times a day, 1 capsule for 1 time, before breakfast meal\[350 mg/day (Bacillus amyloliquefaciens spore 1x10\^9 CFU/day, GF101 200 U/day)\]
- Primary Outcome Measures
Name Time Method Changes of Natural Killer cell activity 8 weeks Natural Killer cell activity was measured in study baseline and 8 week. A ratio of effector cell and target cell was 2.5:1, 5:1, 10:1
(Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100
- Secondary Outcome Measures
Name Time Method Changes of Wisconsin Upper Respiratory Symptom Survey-21 8 weeks Wisconsin Upper Respiratory Symptom Survey-21 consists of seven steps, including individual symptoms, functional quality of life, and overall improvement. Find the sum of the symptom questions and give them the total score. Seek, sum up the questions of life, and get the total quality of life. The sum of the total score of symptoms and the total score of quality of life is also obtained.
Changes of Cytokines 8 weeks For blood Cytokines analysis, collect 3 ml of blood in one SST tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes.
Inspection item were IL-2, IL-12, IFN-γ, TNF-α.
Trial Locations
- Locations (1)
Clinical Trial Center for Functional Foods Chonbuk National University Hospital
🇰🇷Jeonju, Jeollabuk-do, Korea, Republic of